ArticleTherapeutic advances in chronic disease2010
Therapeutic advances in the treatment of nicotine addiction: present and future.
Article in Therapeutic advances in chronic disease, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Success rates with nicotine personal vaporizers: a prospective 6-month pilot study of smokers not intending to quit.BMC public health · 2014Trial
- Impact of an electronic cigarette on smoking reduction and cessation in schizophrenic smokers: a prospective 12-month pilot study.International journal of environmental research and public health · 2013Trial
- Trial
- Effect of an electronic nicotine delivery device (e-Cigarette) on smoking reduction and cessation: a prospective 6-month pilot study.BMC public health · 2011Trial
- Tobacco Smoking or Nicotine Phenotype and Severity of Clinical Presentation at the Emergency Department (SMOPHED): Protocol for a Noninterventional Observational Study.JMIR research protocols · 2024Article
- Nicotine Exposure during Adolescence Leads to Changes of Synaptic Plasticity and Intrinsic Excitability of Mice Insular Pyramidal Cells at Later Life.International journal of molecular sciences · 2021Article
- Rodent models for nicotine withdrawal.Journal of psychopharmacology (Oxford, England) · 2021Review
- Evidence for the Confluence of Cigarette Smoking, Other Substance Use, and Psychosocial and Mental Health in a Sample of Urban Sexual Minority Young Adults: The P18 Cohort Study.Annals of behavioral medicine : a publication of the Society of Behavioral Medicine · 2021Article
- Perceived Safety and Effectiveness of Electronic Cigarettes among Malaysian Adults and Public Support for Regulations.Journal of pharmacy & bioallied sciences · 2020Article
- Lifestyle Vaccines and Public Health: Exploring Policy Options for a Vaccine to Stop Smoking.Public health ethics · 2016Article
- Knowledge and Perceptions about Nicotine, Nicotine Replacement Therapies and Electronic Cigarettes among Healthcare Professionals in Greece.International journal of environmental research and public health · 2016Article
- Metabolic effects of smoking cessation.Nature reviews. Endocrinology · 2016Review
- Putting tobacco harm reduction in perspective: is it a viable alternative?The Indian journal of medical research · 2016Article
- Effectiveness and tolerability of electronic cigarette in real-life: a 24-month prospective observational study.Internal and emergency medicine · 2014Observational
- Achieving appropriate regulations for electronic cigarettes.Therapeutic advances in chronic disease · 2014Review
- Electronic cigarettes and vaping: a new challenge in clinical medicine and public health. A literature review.Frontiers in public health · 2013Review
- A fresh look at tobacco harm reduction: the case for the electronic cigarette.Harm reduction journal · 2013Review
- Handling relapse in smoking cessation: strategies and recommendations.Internal and emergency medicine · 2013Article
- Successful smoking cessation with electronic cigarettes in smokers with a documented history of recurring relapses: a case series.Journal of medical case reports · 2011Article
- Treatment of nicotine addiction: present therapeutic options and pipeline developments.Trends in pharmacological sciences · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
While the proportion of the adult population that smokes has declined steadily in several westernized societies, the rate of successful quit attempts is still low. This is because smokers develop nicotine dependence, a powerful addiction that may require multiple attempts and long-term treatment to achieve enduring abstinence. Currently available first-line agents for smoking cessation therapy include nicotine replacement therapy (available in several formulations, including transdermal patch, gum, nasal spray, inhaler, and lozenge), bupropion (an atypical antidepressant), and varenicline (a partial agonist of the α4β2 nicotinic acetylcholine receptor that was recently developed and approved specifically for smoking cessation therapy). Second-line agents are nortriptyline (a tricyclic antidepressant agent) and the antihypertensive agent clonidine. With the exception of varenicline, which has been shown to offer significant improvement in abstinence rates over bupropion, all of the available treatments appear similarly effective. The adverse event profiles of nortriptyline and clonidine make them more appropriate for second-line therapy, when first-line treatments have failed or are not tolerated. However, the currently marketed smoking cessation drugs reportedly lack high levels of efficacy, particularly in real-life settings. New medications and vaccines with significant clinical advantage are now in the advanced stage of development and offer promise. These include nicotine vaccines and monoamine type B inhibitors. In this review article we discuss current and emerging pharmacotherapies for tobacco dependence focusing on their mechanisms of action, efficacy and adverse event profiles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.